$MNMD
Mind Medicine (MindMed) Inc. Stock $mnmd

$mnmd Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024021656 Filed on February 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.50M	$1.164M	$41.74M
YoY Change	27.06%	-77.04%	38.39%
% of Gross Profit
Research & Development	$11.71M	$21.04M	$52.12M
YoY Change	-7.1%	162.03%	44.11%
% of Gross Profit
Depreciation & Amortization	$527.0K	$790.0K	$3.162M
YoY Change	-33.38%	0.0%	-0.57%
% of Gross Profit
Operating Expenses	$22.20M	$22.21M	$93.87M
YoY Change	6.43%	59.75%	41.51%
Operating Profit	-$22.20M		-$93.87M
YoY Change	6.43%		41.51%
Interest Expense	$434.0K	$1.306M	$4.821M
YoY Change	-64.77%	13.27%	185.27%
% of Operating Profit
Other Income/Expense, Net	-$32.20M	-$2.965M	-$1.866M
YoY Change	714.47%	-137.8%	-119.57%
Pretax Income	-$54.40M	-$23.86M	-$95.73M
YoY Change	119.22%	386.72%	68.55%
Income Tax
% Of Pretax Income
Net Earnings	-$54.40M	-$23.86M	-$95.73M
YoY Change	119.22%	386.72%	68.55%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.14		-$2.44
Diluted Earnings Per Share	-$1.14	-$0.59	-$2.44
COMMON SHARES
Basic Shares Outstanding	41.33M	40.09M	39.16M
Diluted Shares Outstanding	47.86M		39.16M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$252.3M	$99.70M	$99.70M
YoY Change	94.99%	-29.86%	-29.86%
Cash & Equivalents	$252.3M	$99.70M
Short-Term Investments
Other Short-Term Assets	$3.139M	$4.168M	$4.168M
YoY Change	4.49%	6.52%	6.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$255.5M	$103.9M	$103.9M
YoY Change	92.93%	-28.88%	-28.88%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill	$19.92M	$19.92M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$144.0K	$224.0K	$224.0K
YoY Change	-52.0%	-32.33%	-32.33%
Total Long-Term Assets	$20.06M	$20.67M	$20.67M
YoY Change	-13.21%	-13.66%	-13.66%
TOTAL ASSETS
Total Short-Term Assets	$255.5M	$103.9M	$103.9M
Total Long-Term Assets	$20.06M	$20.67M	$20.67M
Total Assets	$275.5M	$124.5M	$124.5M
YoY Change	77.16%	-26.74%	-26.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.595M	$4.136M	$4.136M
YoY Change	227.37%	95.93%	95.93%
Accrued Expenses	$9.974M	$11.63M	$11.63M
YoY Change	49.16%	97.96%	97.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$65.27M	$32.25M	$32.25M
YoY Change	170.87%	80.23%	80.23%
LONG-TERM LIABILITIES
Long-Term Debt	$14.19M	$14.13M	$32.00K
YoY Change
Other Long-Term Liabilities	$15.00K	$32.00K	$14.13M
YoY Change	-98.62%	-97.3%	1093.33%
Total Long-Term Liabilities	$14.21M	$14.16M	$14.16M
YoY Change	1204.41%	1096.03%	1096.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$65.27M	$32.25M	$32.25M
Total Long-Term Liabilities	$14.21M	$14.16M	$14.16M
Total Liabilities	$79.47M	$46.41M	$46.41M
YoY Change	215.56%	143.27%	143.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$344.6M	-$290.2M
YoY Change	57.14%	49.2%
Common Stock	$539.8M	$368.0M
YoY Change	54.68%	6.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$196.1M	$78.13M	$78.13M
YoY Change
Total Liabilities & Shareholders Equity	$275.5M	$124.5M	$124.5M
YoY Change	77.16%	-26.74%	-26.74%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$54.40M	-$23.86M	-$95.73M
YoY Change	119.22%	386.72%	68.55%
Depreciation, Depletion And Amortization	$527.0K	$790.0K	$3.162M
YoY Change	-33.38%	0.0%	-0.57%
Cash From Operating Activities	-$16.60M	-$20.56M	-$64.37M
YoY Change	24.51%	60.04%	28.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$7.529M
YoY Change			-82.2%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	169.2M	2.593M	21.85M
YoY Change	28930.36%	523.32%	-63.0%
NET CHANGE
Cash From Operating Activities	-16.60M	-20.56M	-64.37M
Cash From Investing Activities
Cash From Financing Activities	169.2M	2.593M	21.85M
Net Change In Cash	152.6M	-17.97M	-42.44M
YoY Change	-1298.68%	44.53%	-593.29%
FREE CASH FLOW
Cash From Operating Activities	-$16.60M	-$20.56M	-$64.37M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001813814
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023Q4	us-gaap	Common Stock Value CommonStockValue
CY2022Q4	us-gaap	Common Stock Value CommonStockValue
CY2023Q4	us-gaap	Warrants And Rights Outstanding Valuation Technique Extensible List WarrantsAndRightsOutstandingValuationTechniqueExtensibleList	http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember
CY2022Q4	us-gaap	Warrants And Rights Outstanding Valuation Technique Extensible List WarrantsAndRightsOutstandingValuationTechniqueExtensibleList	http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q2	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40360
CY2023	dei	Entity Registrant Name EntityRegistrantName	Mind Medicine (MindMed) Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1582538
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	One World Trade Center
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 8500
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10007
CY2023	dei	City Area Code CityAreaCode	212
CY2023	dei	Local Phone Number LocalPhoneNumber	220-6633
CY2023	dei	Security12b Title Security12bTitle	Common shares, no par value per share
CY2023	dei	Trading Symbol TradingSymbol	MNMD
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	140000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41334307
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99704000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142142000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4168000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3913000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	103872000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	146055000
CY2023Q4	us-gaap	Goodwill Goodwill	19918000
CY2022Q4	us-gaap	Goodwill Goodwill	19918000
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	527000
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	3689000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	224000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	331000
CY2023Q4	us-gaap	Assets Assets	124541000
CY2022Q4	us-gaap	Assets Assets	169993000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4136000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2111000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11634000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5877000
CY2023Q4	mnmd	Financing Warrants Liability FinancingWarrantsLiability	16476000
CY2022Q4	mnmd	Financing Warrants Liability FinancingWarrantsLiability	9904000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32246000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17892000
CY2023Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	14129000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1184000
CY2023Q4	us-gaap	Liabilities Liabilities	46407000
CY2022Q4	us-gaap	Liabilities Liabilities	19076000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41101303
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41101303
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37979136
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37979136
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	367991000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	344758000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	343000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	627000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-290200000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-194468000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	78134000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	150917000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	124541000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	169993000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52124000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36169000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41742000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30162000
CY2023	us-gaap	Operating Expenses OperatingExpenses	93866000
CY2022	us-gaap	Operating Expenses OperatingExpenses	66331000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-93866000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-66331000
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4664000
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1495000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	157000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	195000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6636000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7843000
CY2023	us-gaap	Other Income OtherIncome	-51000
CY2022	us-gaap	Other Income OtherIncome	2000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1866000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9535000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-95732000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-56796000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-284000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-419000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-96016000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57215000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.44
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.44
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.84
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.84
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39157420
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39157420
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30857463
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30857463
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	151664000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42297000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	206000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-407000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13664000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57215000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	150917000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7823000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	49000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15183000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-96016000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	78134000
CY2023	us-gaap	Profit Loss ProfitLoss	-95732000
CY2022	us-gaap	Profit Loss ProfitLoss	-56796000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15494000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13707000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3162000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3180000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	363000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	148000
CY2022	mnmd	Issuance Costs On Liability Classified Warrants IssuanceCostsOnLiabilityClassifiedWarrants	1500000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6636000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7843000
CY2023	mnmd	Other Non Cash Adjustments OtherNonCashAdjustments	157000
CY2022	mnmd	Other Non Cash Adjustments OtherNonCashAdjustments	43000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-39000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	260000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-51000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	180000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2025000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2056000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5318000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-416000
CY2023	mnmd	Other Liabilities Long Term OtherLiabilitiesLongTerm	1152000
CY2022	mnmd	Other Liabilities Long Term OtherLiabilitiesLongTerm	870000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64365000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50139000
CY2023	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	15000000
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	844000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7529000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42297000
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	17747000
CY2022	mnmd	Payment Of Financing Warrants Issuance Costs PaymentOfFinancingWarrantsIssuanceCosts	1500000
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	114000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	708000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	49000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	206000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	407000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21848000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59051000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	79000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-309000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42438000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8603000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	142142000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	133539000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	99704000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	142142000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	534000
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	128000
CY2023	us-gaap	Stock Issued1 StockIssued1	64000
CY2023	mnmd	Proceeds From Issuance Of Common Shares Under The At The Market Offering Program In Prepaid And Other Current Assets ProceedsFromIssuanceOfCommonSharesUnderTheAtTheMarketOfferingProgramInPrepaidAndOtherCurrentAssets	294000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	194000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DESCRIPTION OF THE BUSINESS</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mind Medicine (MindMed) Inc. (the “Company” or “MindMed”) is incorporated under the laws of the Province of British Columbia. Its wholly owned subsidiaries, Mind Medicine, Inc. (“MindMed US”), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH are incorporated in Delaware, Delaware, Australia and Switzerland respectively. MindMed US was incorporated on May 30, 2019.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company’s mission is to be the global leader in the development and delivery of treatments for brain health disorders that unlock new opportunities to improve patient outcomes. The Company is developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, the Company’s lead product candidates.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">290.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Through December 31, 2023, all the Company’s financial support has primarily been provided by proceeds from the issuance of its common shares, no par value per share (“Common Shares”) and warrants to purchase Common Shares and the Company’s credit facility.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the Company continues its expansion, it may seek additional financing and/or strategic investments; however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. The accompanying consolidated financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of the issuance of these financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards’ effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of the first sale of common equity securities of the issuer under an effective Securities Act of 1933 registration statement or such earlier time that it is no longer an emerging growth company.</span></p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-290200000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.44
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.44
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.84
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.84
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the intangible assets, accrual for research and development costs, and share-based awards and valuation of warrants. Actual results could differ from those estimates, and such differences could be material to the consolidated balance sheets and statements of operations and comprehensive loss.</span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash and cash equivalents. As of December 31, 2023, the Company’s cash equivalents primarily includes a U.S. government money market fund at a high-quality financial institution which invests in highly liquid securities that are issued or guaranteed by the U.S. government or by U.S. government agencies and instrumentalities. The Company's cash is deposited in checking accounts at high-quality financial institutions, which at times, may exceed federally insured limits. Management believes that these financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of December 31, 2023, the Company has not experienced any losses on its cash or cash equivalents.</span></p>
CY2023	mnmd	Business Combination Maximum Measurement Period BusinessCombinationMaximumMeasurementPeriod	P1Y
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	4526000
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	3198000
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P3Y
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	96700000
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	131700000
CY2023Q4	mnmd	Contribution Payable Current ContributionPayableCurrent	2841000
CY2022Q4	mnmd	Contribution Payable Current ContributionPayableCurrent	1566000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2022000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	436000
CY2023Q4	mnmd	Accrued Clinical And Manufacturing Costs AccruedClinicalAndManufacturingCosts	1884000
CY2022Q4	mnmd	Accrued Clinical And Manufacturing Costs AccruedClinicalAndManufacturingCosts	605000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	361000
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-95732000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-56796000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39157420
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39157420
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30857463
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30857463
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12493000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12231692
CY2023	us-gaap	Debt Instrument Interest Rate Terms DebtInstrumentInterestRateTerms	The Term Loan bears a variable interest rate equal to the greater of (i) 10.95% and (ii) the sum of (a) the prime rate as reported in The Wall Street Journal plus (b) 2.95%.
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	700000
CY2023Q4	mnmd	Debt Repayments Of Principal In Year Two Before Unamortized Debt Issuance Cost DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost	4522000
CY2023Q4	mnmd	Debt Repayments Of Principal In Year Three Before Unamortized Debt Issuance Costs DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts	6026000
CY2023Q4	mnmd	Debt Repayments Of Principal In Year Four Before Unamortized Debt Issuance Costs DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts	4452000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15000000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	871000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14129000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	72000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11634000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5877000
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q4	mnmd	Common Stock Shares Issued And Outstanding CommonStockSharesIssuedAndOutstanding	41101303
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	9485000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8958000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	527000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	9485000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5796000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3689000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3200000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3200000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	527000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	527000
CY2023	mnmd	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The Company’s Board of Directors (the “Board”) approved a reverse split of the Company’s Common Shares on a 15-for-1 basis (the “August Share Split”), which was effected on August 26, 2022
CY2022Q3	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	1
CY2022Q2	mnmd	Sale Of Equity Aggregate Public Offering Amount SaleOfEquityAggregatePublicOfferingAmount	200000000
CY2023Q4	mnmd	Sale Of Equity Aggregate Public Offering Additional Amount SaleOfEquityAggregatePublicOfferingAdditionalAmount	59800000
CY2022Q3	mnmd	Common Share And Warrant Public Offering Expire Date CommonShareAndWarrantPublicOfferingExpireDate	2027-09-30
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	14202405
CY2022	mnmd	Weighted Average Fair Value Of Shares Purchased Upon Exercise Of Warrants WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants	11.85
CY2022Q3	mnmd	Common Share And Warrant Public Offering Expire Date CommonShareAndWarrantPublicOfferingExpireDate	2027-09-30
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.872
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.918
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.006
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.028
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.039
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.018
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.042
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.38
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2190315
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.29
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4484000
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	13333
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.95
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7333000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	43800
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.29
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	149454
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	15.29
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1983728
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.26
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	41523000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1217163
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	26.05
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	11973000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.44
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7300000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	603125
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	103455
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-957000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1356000
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	783000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	10742000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2002000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15494000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13707000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	9100000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-89536000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-61763000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6196000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	4967000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-95732000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56796000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-20104000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11926000
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	331000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	51000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	224000
CY2023	mnmd	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	423000
CY2022	mnmd	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	383000
CY2023	mnmd	Effective Income Tax Rate Reconciliation Warrant Fair Value Adjustment EffectiveIncomeTaxRateReconciliationWarrantFairValueAdjustment	-2477000
CY2022	mnmd	Effective Income Tax Rate Reconciliation Warrant Fair Value Adjustment EffectiveIncomeTaxRateReconciliationWarrantFairValueAdjustment	3240000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1732000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14994000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	729000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	730000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	555000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1936000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1618000
CY2023Q4	mnmd	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Issuance Costs DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareIssuanceCosts	2139000
CY2022Q4	mnmd	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Issuance Costs DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareIssuanceCosts	2944000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31560000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25312000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	677000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	638000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	945000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	442000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	13128000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4595000
CY2023Q4	mnmd	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	22000
CY2022Q4	mnmd	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	35000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51023000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36107000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	114000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	32000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	20000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	32000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	94000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	114000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	32000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51000000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14900000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Other Commitment OtherCommitment	28000000
CY2022Q4	us-gaap	Other Commitment OtherCommitment	31600000
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	200000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	200000
CY2022Q2	mnmd	Lessee Operating Lease Option To Extend1 LesseeOperatingLeaseOptionToExtend1	P5Y
CY2022Q2	mnmd	Incremental Borrowing Rate IncrementalBorrowingRate	0.08
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0000950170-24-021656-index-headers.html	Edgar Link	pending
0000950170-24-021656-index.html	Edgar Link	pending
0000950170-24-021656.txt	Edgar Link	pending
0000950170-24-021656-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img133946737_0.jpg	Edgar Link	pending
img133946737_1.jpg	Edgar Link	pending
img133946737_2.jpg	Edgar Link	pending
img194283763_0.jpg	Edgar Link	pending
img216144050_0.jpg	Edgar Link	pending
img216144050_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mnmd-20231231.htm	Edgar Link	pending
mnmd-20231231.xsd	Edgar Link	pending
mnmd-ex23_1.htm	Edgar Link	pending
mnmd-ex31_1.htm	Edgar Link	pending
mnmd-ex31_2.htm	Edgar Link	pending
mnmd-ex32_1.htm	Edgar Link	pending
mnmd-ex32_2.htm	Edgar Link	pending
mnmd-ex3_2.htm	Edgar Link	pending
mnmd-ex4_1.htm	Edgar Link	pending
mnmd-ex4_2.htm	Edgar Link	pending
mnmd-ex97_1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
mnmd-20231231_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MNMD
Mind Medicine (MindMed) Inc. Stock $mnmd

2024 Q1 Form 10-K Financial Statement

#000095017024021656 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNMD Mind Medicine (MindMed) Inc. Stock $mnmd

2024 Q1 Form 10-K Financial Statement

#000095017024021656 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNMD
Mind Medicine (MindMed) Inc. Stock $mnmd